
Tigerlily Foundation's Key Messaging about **Prescription Drug**

Affordability Boards (PDABs)



Prescription Drug Affordability Boards (PDAB) are groups set up by states with the intention to ensure that everyone can get the medicines they need without having to pay too much money. These boards look at how much different medicines cost and decide if they are affordable for people.

Tigerlily supports and advocates for efforts to make sure that drug prices are fair and reasonable, so that no patient has to choose between buying the medicine they need and other important things like food or rent. However, the current model being used for these PDABs raises concerns on benefits actually trickling down to patients and the long-term impact of new life-saving drugs in the future.

Here are Tigerlily's key messages about PDABs:

Patient benefits should be the first priority

Many PDABs create cost savings for the state, hospital or other player, but they don't trickle down to the patient, and patients still have the same co-pays or out-of-pocket costs. Any board needs to prioritize meaningful and actual patient benefits.

Seek out, include and ACT ON patient input

Don't let patient input get lost in the shuffle. Keep patients at the forefront of discussions and continuously seek their valuable insights and act on them through incorporating appropriate changes to address their needs.

Do not use arbitrary Upper Payment Limits (UPLs)

While it might seem like an easy fix, arbitrary payment limits could hinder future drug innovation. Let's ensure the next generation gets access to cutting-edge treatments.

Do not use QALY methods in drug evaluations

This method doesn't capture the true value of life for chronic patients. Let's not diminish the worth of those living with diseases by measuring their value solely on perfect health metrics.

